TODAY'S HEADLINES
FDA is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. In a Jan. 31 safety announcement, the agency said it "has not concluded that FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death." » More |
|
For patients in the early stages of multiple sclerosis, low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a study online January 20, 2014 in JAMA Neurology. » More |
|
A quality improvement initiative, conducted in a primary care setting, dramatically improved asthma control and outcomes for high-risk adolescents, according to a study published online in Pediatrics. » More |
|
FDA approved a 40 mg/mL dose of glatiramer acetate injection (Copaxone, Teva Pharmaceutical Industries Ltd.) to be used three times a week for patients with relapsing forms of multiple sclerosis. » More |
Continuing Education
This month, Drug Topics offers “Clinical Updates in Diabetes Care,” a knowledge-based activity worth up to 2 credits. The goal of this activity is to assist pharmacists in recognizing and understanding the changes in diabetes care to provide optimal evidence-based care for patients with diabetes. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career. |
|
|
Like
Tweet
